Eternity in Medical Information -- Medisurf
Search | Web Directory, News, Variable useful Information, PubMed In Medine, All
Category Select :
Items 121 ~ 140 of 26060, Page 7 of 1303
121. Merck Hosts 2019 Investor Day Outlining Business Momentum, Strong Expected Growth and Focus on Innovative Research and Development
06/20/2019 MERCK
122. Medtronic Statement Regarding FDA Circulatory System Devices Panel
Medical Devices Advisory Committee on paclitaxel-coated therapies in patients with peripheral artery disease (PAD) in the superficial femoropopliteal artery (SFA)
06/20/2019 Medtronic
123. AAOS Opposition Statement to Senate HELP Surprise Billing Proposal
06/20/2019 American Academy of Orthopaedic Surgeons
124. WHO flags critical funding gap, calls for political parties to join fight against Ebola
WHO Director-General briefs Members States on situation in DRC and appeals for funding for the Ebola response
06/19/2019 WHO
125. AstraZeneca and Merck’s LYNPARZA® (olaparib) Approved in Japan as First-Line Maintenance Therapy in Patients with BRCA-Mutated Advanced Ovarian Cancer
LYNPARZA is the Only PARP Inhibitor Approved in Japan
06/19/2019 MERCK
126. Volleyball: An All-American Sport
Volleyball is fun, demanding, burns lots of calories, and has a low risk of injury. Find out how this uniquely American sport can be part of your active lifestyle.
06/19/2019 American Cancer Society
127. Abbott Hosts Conference Call for Second-Quarter Earnings
ABBOTT PARK, Ill., June 19, 2019 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its second-quarter 2019 financial results on Wednesday, July 17, 2019, before the market opens.
06/19/2019 Abbott
128. In the face of slow progress, WHO offers a new tool and sets a target to accelerate action against antimicrobial resistance
06/18/2019 WHO
129. 1 in 3 people globally do not have access to safe drinking water ? UNICEF, WHO
New report on inequalities in access to water, sanitation and hygiene also reveals more than half of the world does not have access to safe sanitation services.
06/18/2019 WHO
130. LYNPARZA® (olaparib) Approved in the EU for Use as First-Line Maintenance Therapy in Patients With BRCA-Mutated Advanced Ovarian Cancer
AstraZeneca and Merck’s LYNPARZA Reduced the Risk of Disease Progression or Death by 70% Compared to Placebo Following Response to Platinum-Based Chemotherapy in Phase 3 SOLO-1 Trial / LYNPARZA is the Only PARP Inhibitor Approved in the EU for This Indication
06/18/2019 MERCK
131. FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as Monotherapy for Patients with Metastatic Small Cell Lung Cancer (SCLC) with Disease Progression on or After Platinum-Based Chemotherapy and at Least One Other Prior Line of Therapy
Marks First Approval for KEYTRUDA in SCLC
06/18/2019 MERCK
132. Many Cancer Survivors Struggle to Pay For Care
The population of cancer survivors in the US is growing, and many struggle to pay health care costs. A study led by the Centers for Disease Control and Prevention (CDC) finds one-fourth of survivors have problems paying medical bills and one-third worry about them.
06/18/2019 American Cancer Society
133. Abbott Launches First-ever Rapid Point-of-Care HbA1c Test to Aid in the Diagnosis of Diabetes
Afinion™ HbA1c Dx test provides results in three minutes, enabling clinicians to develop informed, individualized care plans during patient consultation / Assay is the first and only rapid point-of-care test cleared by the U.S. Food and Drug Administration (FDA) to aid healthcare professionals in the diagnosis of diabetes
06/17/2019 Abbott
134. FDA Approves Keytruda (Pembrolizumab) for Head and Neck Cancer
The US Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab) as a first-line treatment for people with advanced head and neck cancer.
06/14/2019 American Cancer Society
135. Abbott Declares 382ⁿ? Consecutive Quarterly Dividend
ABBOTT PARK, Ill., June 14, 2019 /PRNewswire/ --?The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 32 cents per share.
06/14/2019 Abbott
136. IBM, KPMG, Merck and Walmart to collaborate as part of FDA’s program to evaluate the use of blockchain to protect pharmaceutical product integrity
The FDA pilot program explores innovative and emerging approaches for the tracing and verification of prescription products
06/13/2019 MERCK
137. AMA policy advocates to eliminate non-medical vaccine exemptions
The AMA adopted policy to actively advocate for legistration, and policies thah incentivize states to eliminte non-medical exemptions from immunizations.
06/13/2019 American Medical Association (AMA)
138. All Black Women in the United States May Not Have the Same Level of Risk for Triple-Negative Breast Cancer
We've known for a while that triple-negative breast cancer is more common in black women in the United States, compared to other groups. The news is the prevalence varies significantly depending on where these women were born. American Cancer Society (ACS) researchers found that among black women, those born in the US and Western Africa were diagnosed more often with triple-negative breast cancer than women born in East Africa. The authors published their findings in Cancer, an ACS peer-reviewed journal.
06/13/2019 American Cancer Society
139. New study finds no link between HIV infection and contraceptive methods
06/13/2019 WHO
140. MRI Plays A Role in Diagnosis of Cocaine-related Damage to the Heart
Cardiac MRI can detect cocaine's effects on the cardiovascular system and help differentiate between acute and chronic conditions. / Cocaine abuse can have devastating effects on the heart.
06/13/2019 Radiological Society of North America
1 2 3 4 5 6 7 8 9 10
경기도 성남시 분당구 구미동 25-1 엘레강스 프라자 ㈜ 메디서프 | Tel : 031-896-0930 | 사업자 등록번호 : 212-81-47247
통신판매신호번호 : 경기 성남 2007-712 | 대표이사 한상욱